Prostamax (Bioregulator)

Prostamax is a synthetic tetrapeptide (Lys-Glu-Asp-Pro) from the Khavinson class of bioregulatory peptides developed at the Saint Petersburg Institute of Bioregulation and Gerontology. It is designed to target prostate tissue through proposed peptide-DNA interactions that modulate gene expression in prostatic epithelial cells. Prostamax has been investigated in Russian biogerontology research examining age-related changes in prostate function and tissue homeostasis. The Khavinson model proposes that the Lys-Glu-Asp-Pro sequence can penetrate cells and interact with DNA regulatory regions, influencing transcription of prostate-specific genes. It is one of several organ-specific tetrapeptides in the Khavinson bioregulator family, each designed with a unique sequence to target distinct tissue types through proposed tissue-selective gene regulatory mechanisms.

Prostamax has been investigated for its proposed interactions with gene regulatory regions in prostate epithelial cells. The Khavinson bioregulatory model proposes that the Lys-Glu-Asp-Pro sequence penetrates cell membranes and interacts with specific DNA sequences in promoter regions of prostate-expressed genes. Researchers from the Saint Petersburg group observed that Prostamax treatment in prostate cell culture models was associated with changes in expression of tissue-specific differentiation markers and cellular homeostasis genes. Studies suggest that the peptide may influence the balance between proliferative and differentiated states in prostatic epithelium. The proline residue at the C-terminus confers conformational constraints on the peptide backbone, which may influence its DNA-binding specificity in the bioregulatory model. These effects are attributed to epigenetic gene regulation rather than conventional receptor signaling pathways.

Prostate Tissue Biology

Khavinson et al. (2006) investigated Prostamax in prostate tissue models and observed changes in gene expression related to prostate function and cellular homeostasis [1].

Bioregulatory Peptide Framework

Khavinson VK (2002) described the comprehensive model for tissue-specific bioregulatory peptides including those targeting urogenital tissues [2].

Peptide-DNA Interactions

Khavinson et al. (2014) reviewed evidence for short peptide regulation of gene expression through epigenetic mechanisms across multiple tissue types [3].